21 countries talk about "dual channels", and Chinese medicine accounts for half

Author:Kenji Bureau Time:2022.09.06

On September 1, the Jiangxi Provincial Medical Insurance Bureau issued the "Notice on Dynamic Adjustment Part of the Drug Classification Management", involving 52 national medical insurance negotiation drugs.

From the perspective of publicity content, 21 products including Fuma Nonora, Etage Clean tablets, Alizantin tablets, and thermosoning agents will be transferred out of the province's "dual -channel drug" list. The Jiangxi Provincial Medical Insurance Bureau announced a week ago, saying that adjustments are based on "the management principles of drug classification of negotiations in our province and application for some enterprises."

The "dual channel" policy was set up by the National Medical Insurance Bureau to solve the "difficulty in entering the hospital" and "difficulty in buying medicines" in the negotiation variety. All provinces and cities have selected negotiating drugs with high clinical value, urgent need for patients, and low alternatives to enter the "dual channel" management, and dynamically adjust according to the situation.

It is not the first time that Jiangxi has carried out dual -channel drug adjustments, and has been adjusted five or six times. Many medicines are brought up with dual channels, why is it?

Traditional Chinese medicine accounts for half of the varieties of the variety

Jiangxi's national conversation medicine is set as three categories of ABC, of which Class A is reimbursed at the highest percentage; after the patient pays 10%of the patient, it will be reimbursed at the highest proportion. Class C is not included in the scope of the "dual channel" management. According to the country Category B reimbursement.

Judging from this publicity content, 23 drugs involve adjustments within the scope of the "dual channel" management; 8 of the 29 drugs are adjusted and 21 are transferred.

Among the varieties, more than half of the traditional Chinese medicines include 13 products including the heated thermal Ningxin agent caused by the heated discussion in the treatment of Chinese medicine in Shaanxi New Crown Pneumonia.

It is worth mentioning that the three products of Qihuangtong secret soft capsules, lipid -reducing Tongluo soft capsules, and dan lantern brain soft capsules are all from the same pharmaceutical company -Shenwei Pharmaceutical, and they are all Its exclusive innovation variety.

Shenwei Pharmaceutical Group is a large -scale comprehensive enterprise group based on modern Chinese medicine. It has been selected as the "top 20 Chinese traditional Chinese medicine companies in 2021. The data of the first half of this year shows that Qi Huangtong's secret soft capsules, lipid -lowering Tongluo soft capsules During the period of the Dan Lantern Lantern Capsules, the revenue during the period was 30.63 million yuan, 16.63 million yuan, and 13.97 million yuan, respectively, an increase of 69.2%, 114.4%, and 110.5%over the same period last year.

However, the good times did not last long. The Jianzhi Bureau learned that the lipid -lowering Tongluo soft capsule appeared in the list of drugs from Chongqing Medical Insurance at the end of last year, and has stopped medical insurance reimbursement since the beginning of this year. It is expected that at the end of this year, the medical insurance directory will be exited as a whole nationwide.

The Shenwei Group has been in the business with the business of injections, Chinese medicine formula particles. The company's 2021 annual report shows that the revenue of various types of soft capsule products in Shenwei Group accounts for 15.04%. If the fat reduction Tongluo soft capsule withdraws from the medical insurance, relying on the layout of Shenwei in the field of terminal sales, it is expected that it will not affect it in a controllable range.

The Jianzhi Bureau found that more than one of the "dual channels" of Jiangxi's "dual channels" was removed from the medical insurance catalog, and the heart Malong injection of Yunnan Pharmaceutical Pharmaceuticals was also withdrawn from the medical insurance variety.

"Dual channels" pain in the ground

Since January 2022, Jiangxi Province has released five batches of "dual -channel drugs" to call out list, involving 38 drugs that actively apply for exit, of which there are many sulburi non -gogti, paclitaxel, and Akab candy 2021 in 2021 in 2021 in 2021. China's public medical institution terminal sales exceeding 2 billion yuan.

In June, Jianzhi Bureau contacted relevant companies that the main reason for the exit of pharmaceutical companies was that the patient's purchase of some "dual -channel" drugs could not brush medical insurance or achieve medical insurance reimbursement. At the same time, because the price of Class B drugs is relatively low, for enterprises, there is no difference between "walking dual -channel or medical insurance."

According to the State Medical Insurance Bureau, the "dual -channel" drugs are simultaneously incorporated into medical insurance payment, and the reimbursement policies of designated hospitals and fixed -point retail pharmacies are the same. The pharmacy has added pharmaceutical sales channels, but it still encounters problems with difficulty in landing.

Some industry media surveyed the operating conditions of 855 "dual -channel" stores of 55 chain pharmacies. The results showed that only 8 of the 55 companies were in compliance with business expectations, accounting for less than 15%. These eight companies are either regional pharmaceutical circulation companies with channels and varieties, or they are chain pharmacies that have an earlier layout of DTP professional pharmacies.

Among them, payment obstacles are important reasons for the difficulty of "dual -channel" drug operations. 30%of pharmacies believe that the medical insurance department and hospitals are not coordinated properly, causing "dual -channel" drugs to have no hospital prescription and cannot swipe the medical insurance card.

Other problems come from prescription source obstacles. 23.10%of the pharmacies said that the hospital's prescription outflow was limited, and the drugs were banned from purchasing outside the hospital.

The biggest difficulty of the dual -channel policy is whether public hospitals are willing to give up the interests that can be seen in front of them. However, most companies are still optimistic about this policy. Some corporate people told the Jianzhi Bureau, "The policy intention is good, but it has only encountered a little difficulty for the time being."